These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8695265)

  • 1. Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia.
    Jung K; Lein M; Weiss S; Schnorr D; Henke W; Loening S
    Eur J Cancer; 1996 Apr; 32A(4):627-30. PubMed ID: 8695265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble CD44 variants in the serum of patients with urological malignancies.
    Lein M; Jung K; Weiss S; Schnorr D; Loening SA
    Oncology; 1997; 54(3):226-30. PubMed ID: 9143404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble CD44 splice variants and pelvic lymph node metastasis in ovarian cancer patients.
    Stickeler E; Vogl FD; Denkinger T; Mobus VJ; Kreienberg R; Runnebaum IB
    Int J Mol Med; 2000 Nov; 6(5):595-601. PubMed ID: 11029531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased soluble CD44 concentrations are associated with larger tumor size and lymph node metastasis in breast cancer patients.
    Mayer S; zur Hausen A; Watermann DO; Stamm S; Jäger M; Gitsch G; Stickeler E
    J Cancer Res Clin Oncol; 2008 Nov; 134(11):1229-35. PubMed ID: 18438684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Volume of normal prostate, of prostate cancer, and of benign prostatic hyperplasia: are correlations with prostate specific antigen clinically useful?
    Clements R; Penney MD; Etherington RJ; Griffiths GJ; Hughes H; Peeling WB
    Prostate Suppl; 1992; 4():51-7. PubMed ID: 1374178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement.
    Murphy GP; Holmes EH; Boynton AL; Kenny GM; Ostenson RC; Erickson SJ; Barren RJ
    Prostate; 1995 Mar; 26(3):164-8. PubMed ID: 7534919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serological evaluation of soluble CD44 in renal cancer.
    Kan M; Kanayama H; Naruo S; Tsuji M; Kojima K; Kurokawa Y; Kagawa S
    Jpn J Cancer Res; 1996 Nov; 87(11):1191-4. PubMed ID: 9045950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer.
    Jung K; Nowak L; Lein M; Priem F; Schnorr D; Loening SA
    Int J Cancer; 1997 Apr; 74(2):220-3. PubMed ID: 9133459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble CD44 v5 and v6 in serum of patients with breast cancer. Correlation with expression of CD44 v5 and v6 variants in primary tumors and location of distant metastasis.
    Lackner C; Moser R; Bauernhofer T; Wilders-Truschnig M; Samonigg H; Berghold A; Zatloukal K
    Breast Cancer Res Treat; 1998 Jan; 47(1):29-40. PubMed ID: 9493973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.
    Li J; Dai L; Lei N; Xing M; Li P; Luo C; Casiano CA; Zhang JY
    Oncotarget; 2016 Jul; 7(28):43546-43556. PubMed ID: 27286458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble CD44 isoforms in serum as potential markers of metastatic gastric carcinoma.
    Harn HJ; Ho LI; Shyu RY; Yuan JS; Lin FG; Young TH; Liu CA; Tang HS; Lee WH
    J Clin Gastroenterol; 1996 Mar; 22(2):107-10. PubMed ID: 8742647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
    Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH
    Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels of v5 and v6 CD44 splice variants in serum of patients with colorectal cancer are not correlated with pT stage, histopathological grade of malignancy and clinical features.
    Zalewski B
    World J Gastroenterol; 2004 Feb; 10(4):583-5. PubMed ID: 14966921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PR92 antigen in human prostate fluid: elevated levels in prostate cancer.
    Carlin BI; Marachie J; Venegas MF; Schaeffer AJ; Shaw N; Hass GM; Rademaker AW; Lee C; Grayhack JT
    Prostate; 1994 Sep; 25(3):156-61. PubMed ID: 7520579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate stem cell antigen (PSCA) mRNA expression in peripheral blood in patients with benign prostatic hyperplasia and/or prostate cancer.
    Fawzy MS; Mohamed RH; Elfayoumi AR
    Med Oncol; 2015 Mar; 32(3):74. PubMed ID: 25698533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antibody response to Propionibacterium acnes is an independent predictor of serum prostate-specific antigen levels in biopsy-negative men.
    Shannon BA; Cohen RJ; Garrett KL
    BJU Int; 2008 Feb; 101(4):429-35. PubMed ID: 17850358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
    Haese A; Graefen M; Noldus J; Hammerer P; Huland E; Huland H
    J Urol; 1997 Dec; 158(6):2188-92. PubMed ID: 9366341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
    Kopp R; Classen S; Wolf H; Gholam P; Possinger K; Wilmanns W
    Anticancer Res; 2001; 21(4B):2995-3000. PubMed ID: 11712800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levels of circulating intercellular adhesion molecule-1 in patients with metastatic cancer of the prostate and benign prostatic hyperplasia.
    Wolff JM; Stephenson RN; Chisholm GD; Habib FK
    Eur J Cancer; 1995; 31A(3):339-41. PubMed ID: 7540402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.